Tags

Type your tag names separated by a space and hit enter

Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Ophthalmic Surg Lasers Imaging Retina. 2016 09 01; 47(9):836-9.OS

Abstract

BACKGROUND AND OBJECTIVE

To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA).

PATIENTS AND METHODS

A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept.

RESULTS

Eyes received an average of 16 prior injections (range: three injections to 31 injections; median: 17 injections). The mean central subfoveal thickness (CST) improved from 453 µm at the time of first anti-vascular endothelial growth factor (VEGF) injection (range: 304 µm to 686 µm; median: 429 µm), to 374 µm at the time of the switch to aflibercept (range: 267 µm to 547 µm; median: 361 µm; P = .02), to 332 µm after the first aflibercept injection (range: 242 µm to 545 µm; median: 318 µm; P < .001). Visual acuity improved after switching to aflibercept at the first follow-up visit (logMAR 0.40 [Snellen equivalent 20/50]) to logMAR 0.35 (Snellen equivalent 20/45) (P = .044).

CONCLUSIONS

In eyes with persistent DME treated with ranibizumab and/or bevacizumab, switching to aflibercept may further improve macular thickness. Given the cost difference between the three drugs, a randomized trial evaluating a stepwise approach may be worthwhile. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:836-839.].

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27631479

Citation

Shah, Chirag P., and Jeffrey S. Heier. "Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/or Bevacizumab May Further Improve Macular Thickness." Ophthalmic Surgery, Lasers & Imaging Retina, vol. 47, no. 9, 2016, pp. 836-9.
Shah CP, Heier JS. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. Ophthalmic Surg Lasers Imaging Retina. 2016;47(9):836-9.
Shah, C. P., & Heier, J. S. (2016). Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. Ophthalmic Surgery, Lasers & Imaging Retina, 47(9), 836-9. https://doi.org/10.3928/23258160-20160901-06
Shah CP, Heier JS. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/or Bevacizumab May Further Improve Macular Thickness. Ophthalmic Surg Lasers Imaging Retina. 2016 09 1;47(9):836-9. PubMed PMID: 27631479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. AU - Shah,Chirag P, AU - Heier,Jeffrey S, PY - 2016/05/15/received PY - 2016/07/01/accepted PY - 2016/9/16/entrez PY - 2016/9/16/pubmed PY - 2017/7/6/medline SP - 836 EP - 9 JF - Ophthalmic surgery, lasers & imaging retina JO - Ophthalmic Surg Lasers Imaging Retina VL - 47 IS - 9 N2 - BACKGROUND AND OBJECTIVE: To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept. RESULTS: Eyes received an average of 16 prior injections (range: three injections to 31 injections; median: 17 injections). The mean central subfoveal thickness (CST) improved from 453 µm at the time of first anti-vascular endothelial growth factor (VEGF) injection (range: 304 µm to 686 µm; median: 429 µm), to 374 µm at the time of the switch to aflibercept (range: 267 µm to 547 µm; median: 361 µm; P = .02), to 332 µm after the first aflibercept injection (range: 242 µm to 545 µm; median: 318 µm; P < .001). Visual acuity improved after switching to aflibercept at the first follow-up visit (logMAR 0.40 [Snellen equivalent 20/50]) to logMAR 0.35 (Snellen equivalent 20/45) (P = .044). CONCLUSIONS: In eyes with persistent DME treated with ranibizumab and/or bevacizumab, switching to aflibercept may further improve macular thickness. Given the cost difference between the three drugs, a randomized trial evaluating a stepwise approach may be worthwhile. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:836-839.]. SN - 2325-8179 UR - https://www.unboundmedicine.com/medline/citation/27631479/Aflibercept_for_Diabetic_Macular_Edema_in_Eyes_Previously_Treated_With_Ranibizumab_and/or_Bevacizumab_May_Further_Improve_Macular_Thickness_ L2 - https://www.healio.com/doiresolver?doi=10.3928/23258160-20160901-06 DB - PRIME DP - Unbound Medicine ER -